Harmonix

AI acceleration of scientific innovation and commercialization. Life Extension ventures invests in the two largest sectors in the world, People and Planet, where AI suddenly matters. Novel commercialization through marketplaces, networks, Web3, personalizations, payments, APIs, new go-to-markets and operations. Software, AI, and the power of the Internet will accelerate the adoption and monetization of science breakthroughs on human and planetary life. New infrastructure like SaaS, data platforms, OSs, LLMs, collaboration tools, storage, simulations, GenAI, visualization tools, security, workflow automation, Web3 and DAOs, or design tools to accelerate innovations. We target the infrastructure that accelerates the innovations. Software and AI are reinventing many industries bringing benefits to society and creating new category defining multibillion dollar companies; and now is the turn of climate, biology and health.

We invest in opportunities backed by deep science. Xora is an early-stage investment platform of Temasek. We typically invest as a lead or co-lead investor in the Seed and Series A rounds, and later rounds (via our parent company). While we are not limited by geography, we prioritize opportunities that possess a strong linkage with the Singapore science & technology ecosystem. Leveraging the Temasek global network of investors and operating companies, we are active partners to ambitious founders building the next generation of impactful, world-changing companies. Our Team Our team possesses strong technical domain expertise in both physical and life sciences, and the intersection thereof, and are steeped in the nuances of early-stage deep science investing and venture building. We are global citizens with business experience in major markets. Our principles guide our engagement process and our investment decisions.We start with the people on the journey and a shared vision of the future. ​ We look for dogged persistence, unbounded creativity, acute self-awareness, a sense of urgency, and a passion for impact. We embrace both the technical and people complexity of science-based opportunities. ​ We welcome early and frequent contact and appreciate the opportunity to inform an emerging narrative. ​ We prefer brainstorming to pitches, and relationships to transactions. ​ We commit more than capital; we pledge our mindshare and our network.

We invest in groundbreaking medicines across disease area, financing stage, and geography, with a focus on programs in, or about to enter, human trials. We are curious, rigorous, collaborative, and passionate about our work; we are also long-term investors in our team.

Our mission is to serve as a catalyst for innovation by providing early-stage strategic capital and expert guidance to visionary entrepreneurs and researchers. We're committed to propelling revolutionary technologies and treatments poised to transform healthcare and significantly enhance the lives of patients and their families. About Us At Shannon Life Sciences, we are driven by a passion for innovation. We specialize in identifying and supporting early, groundbreaking ideas that have the potential to revolutionize the treatment of patients. Our team is a mosaic of experts in healthcare, finance, and entrepreneurship. This diverse expertise, coupled with a deep understanding of the healthcare sector and the intricacies of bringing novel therapies to market, positions us to help enable our portfolio companies to be successful. Our role extends beyond funding. We actively engage with academic institutions, visionary entrepreneurs, and industry leaders, forging partnerships that propel cutting-edge therapies and technologies into the healthcare arena.

Biospring Partners was founded in 2020 to invest in companies with the potential to fundamentally shift how technology is utilized across the life sciences sector. Michelle Dipp and Jennifer Lum came together to combine their experience in healthcare, technology, investing and operations to offer a differentiated approach to growth equity. Expanding the potential of life sciences technology We focus on identifying long-term themes within life sciences technology. We build trusted partnerships with management teams to support the growth of their businesses. Sectors we invest in Biospring invests in growth-stage B2B companies that are driving innovation across the life sciences industry and beyond. Our Approach We are a trusted partner that thrives in building long term strategic partnerships. We work closely alongside our companies to broaden their ambition and strengthen their path to growth. Our Investment Criteria$10M+ in annual revenue 30%+ revenue growth Diverse customer base

InnoCom makes investments into worthy Life Science companies, providing: Investment opportunities in cutting edge technologies Access to early commercialization for life Science innovators Capital of $3 to 15 Million USD initial tranche for a company to complete its R&D, Preclinical & Phase I Trials; additional funding to complete Phase II Trials to take products to Licensing Industry networking to access revenue at 2-3 years following pre-clinical trials Providing revenue and/or takeout at 7 years end of clinical trials Business Counsel and advice to the company management team Corporate Officer participation, setting up strong Systems, Procedures, and Protocols Board of Directors Membership, building strong Corporate Governance Life Science Expertise, providing commercialization at the end of Preclinical and/or Clinical I & II Trials at 2-3 years Licensing Upfront Fees at 3 years, Revenue and/or Takeout at end of Clinical Trials at 7 years Enhancing the delivery of health solutions to the patients who need them